European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment - Sorbonne Université
Article Dans Une Revue European Child and Adolescent Psychiatry Année : 2021

European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment

Heike Eichele
  • Fonction : Auteur
Jeremy S Stern
  • Fonction : Auteur
Liselotte Skov
  • Fonction : Auteur
Renata Rizzo
  • Fonction : Auteur
Nanette Mol Debes
  • Fonction : Auteur
Péter Nagy
  • Fonction : Auteur
Andrea E Cavanna
Cristiano Termine
  • Fonction : Auteur
Alexander Münchau
  • Fonction : Auteur
Natalia Szejko
Danielle Cath
Kirsten R Müller-Vahl
  • Fonction : Auteur
Cara Verdellen
  • Fonction : Auteur
Andreas Hartmann
Aribert Rothenberger
  • Fonction : Auteur
Pieter J Hoekstra
  • Fonction : Auteur
Kerstin J Plessen
  • Fonction : Auteur

Résumé

In 2011, the European Society for the Study of Tourette Syndrome (ESSTS) published the first European guidelines for Tourette Syndrome (TS). We now present an update of the part on pharmacological treatment, based on a review of new literature with special attention to other evidence-based guidelines, meta-analyses, and randomized double-blinded studies. Moreover, our revision took into consideration results of a recent survey on treatment preferences conducted among ESSTS experts. The first preference should be given to psychoeducation and to behavioral approaches, as it strengthens the patients' self-regulatory control and thus his/her autonomy. Because behavioral approaches are not effective, available, or feasible in all patients, in a substantial number of patients pharmacological treatment is indicated, alone or in combination with behavioral therapy. The largest amount of evidence supports the use of dopamine blocking agents, preferably aripiprazole because of a more favorable profile of adverse events than first-and second-generation antipsychotics. Other agents that can be considered include tiapride, risperidone, and especially in case of co-existing attention deficit hyperactivity disorder (ADHD), clonidine and guanfacine. This view is supported by the results of our survey on medication preference among members of ESSTS, in which aripiprazole was indicated as the drug of first choice both in children and adults. In treatment resistant cases, treatment with agents with either a limited evidence base or risk of extrapyramidal adverse effects might be considered, including pimozide, haloperidol, topiramate, cannabis-based agents, and botulinum toxin injections. Overall, treatment of TS should be individualized, and decisions based on the patient's needs and preferences, presence of co-existing conditions, latest scientific findings as well as on the physician's preferences, experience, and local regulatory requirements.
Fichier principal
Vignette du fichier
Roessner2021_Article_EuropeanClinicalGuidelinesForT.pdf (818.56 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03454248 , version 1 (29-11-2021)

Identifiants

Citer

Veit Roessner, Heike Eichele, Jeremy S Stern, Liselotte Skov, Renata Rizzo, et al.. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment. European Child and Adolescent Psychiatry, 2021, ⟨10.1007/s00787-021-01899-z⟩. ⟨hal-03454248⟩
23 Consultations
110 Téléchargements

Altmetric

Partager

More